Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus.
The feasibility of using a trans-dominant interfering human immunodeficiency virus type 1 (HIV-1) envelope mutant for inducible gene therapy of HIV infection was investigated. Genes encoding wild-type or mutant glycoproteins were introduced into CD4+ cells, where they were stably maintained but not expressed until induced. Envelope (env) gene expression was dependent upon the viral regulatory protein Tat. Induction of the mutant env resulted in resistance to cytopathic effects mediated by wild-type envelope and decreased infectious vector virus production. When cells containing the mutant env gene were infected with wild-type virus, viral spread was inhibited. The fact that maintenance of the env gene was stable over time suggests that inducible gene therapy using the dominantly interfering env mutant may be a feasible approach to slowing the progression of HIV-1 disease.
McArdle Laboratory for Cancer Research, University of Wisconsin, Madison 53706.
G L
GL
Buchschacher
E O
EO
Freed
A T
AT
Panganiban
D015496:CD4-Positive T-Lymphocytes / Q000382:microbiology; D005455:Fluorescent Antibody Technique; D015870:Gene Expression; D015726:Giant Cells / Q000382:microbiology; D015700:HIV Envelope Protein gp41 / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics* / Q000502:physiology; D006367:HeLa Cells; D006801:Humans; D009154:Mutation; D011233:Precipitin Tests; D014779:Virus Replication / Q000235:genetics
D015700:HIV Envelope Protein gp41